Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
BVES Double Nickase Plasmid (h): sc-403698-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BVES Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- BVES Double Nickase Plasmid (h) and BVES Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting BVES. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BVES Antibody (E-3): sc-374081
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BVES Double Nickase Plasmid (h) | sc-403698-NIC | 20 µg | $410.00 | |||
BVES Double Nickase Plasmid (h2) | sc-403698-NIC-2 | 20 µg | $410.00 |
BVES (blood vessel epicardial substance), also known as POPDC1, encodes a membrane-associated protein enriched in epithelial and muscle tissues that contributes to cell–cell adhesion, membrane organization, and regulation of signaling microdomains. BVES participates in cyclic nucleotide–responsive processes and interfaces with pathways controlling cytoskeletal dynamics, tight junction integrity, and epithelial polarization, influencing cell motility and tissue architecture. Altered BVES expression or localization has been associated with disrupted epithelial homeostasis and changes in proliferative and migratory phenotypes, making it relevant to studies of tumor biology and tissue remodeling. In cardiovascular and smooth muscle contexts, BVES has been linked to stress-responsive signaling and conduction-related physiology, supporting its use in models of muscle development and function.
BVES Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the BVES locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within BVES. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt BVES function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of BVES-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.